Kala Pharmaceuticals Presents At The Ophthalmology Innovation Summit

Kala Pharmaceuticals Presents At The Ophthalmology Innovation Summit

Kala Pharmaceuticals, Inc., a pharmaceutical company committed to developing innovative ophthalmic products supported by its proprietary mucus-penetrating particle (MPP) technology, has recently announced that Charlie McDermott, who is the Interim President and Chief Business Officer of Kala, participated in the Ophthalmology Innovation Summit held in San Diego, CA.

McDermott talked about Kala’s MPP technology and its novel nanoparticle formulation of loteprednol etabonate (“LE”), their lead candidate KPI-121. The panel in which McDermott was included was called “Spotlight on Drug Delivery,” and took place between 2:10 and 2:50 PM Pacific Daylight Time.

In addition, McDermott delivered highlights on the positive data of KPI-121 and discussed its Phase 3 results concerning the treatment of pain and inflammation in individuals who underwent cataract surgery, along with the outcomes of a Phase 2 trial in patients suffering with dry eye syndrome.

The Ophthalmology Innovation Summit hosts the representatives of companies advancing ground-breaking ophthalmic technologies, linking them with physicians and business leaders in the area that are driving ophthalmic innovation.

Notes About KPI-121

KPI-121 is a new nanoparticle formulation of loteprednol etabonate that uses Kala’s MPP technology to facilitate the penetration into target tissues of the eye. KPI-121 has already been studied in several clinical trials, including 1 percent and 0.25 percent formulations to treat post-surgical pain and ocular inflammation and a 0.25 percent formulation for dry eye and meibomian gland disease.

Read More Recent News

LENSAR, Inc., developers of next generation femtosecond laser technology for refractive cataract surgery, have announced its receipt of 510k clearance from the U.S. Food and Drug Administration (FDA) for a suite of five new application technologies incorporated in the company’s LENSAR Laser System flagship product, heralded as the first femtosecond laser cataract platform enabling automation of several surgical procedure planning and execution elements.

Leave a Comment